Prolific Machines, a biotechnology company specializing in photo molecular biology, has raised USD 54.6 million in series B funding led by The Ki Tua Fund. Breakthrough Energy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Conti Ventures, and In-Q-Tel (IQT) participated.
Prolific Machines will use the funding for commercialization and customer acquisition, marking the company’s transition from proving the efficacy of its process to actively delivering it to people.
Prolific Machines enable the transition from expensive and hard-to-control molecules to a more efficient and sustainable method—light. Through its bioreactors, it offers customers efficient biomanufacturing of high-value bioproducts, including nutritional proteins, antibodies for disease treatment, and cultivated meat.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.